< Back to Press

ASCENSIA DIABETES CARE LAUNCHES THE 6 MONTH EVERSENSE^® E3 CONTINUOUS GLUCOSE MONITORING SYSTEM IN THE U.S. WITH THE NEW EVERSENSE PASS SAVINGS PROGRAM

Parsippany, United States

Ascensia Diabetes Care, a global diabetes care company, announces that it has launched the next-generation Eversense^® E3 Continuous Glucose Monitoring (CGM) System for patients in the U.S., alongside the new Eversense PASS savings program. Eversense E3, which is developed by Senseonics Holdings, Inc. (NYSE American: SENS), was approved for use up to 6 months by the U.S. Food and Drug Administration (FDA) earlier this year, making it the longest lasting CGM sensor available in the U.S.

To increase patient access to the Eversense E3 CGM System and its benefits, Ascensia has designed and introduced Eversense PASS, a new Payment Assistance and Simple Savings Program*. Under the program, Eversense users will only pay $99 out of pocket for their first Eversense E3 Sensor and Smart Transmitter. For each sensor thereafter, users pay no more than $100 per month, or $600 for the duration of each sensor wear. Potential Eversense E3 users can go to www.ascensiadiabetes.com/eversense to learn more about the program and find out if they are eligible.

Robert Schumm, President at Ascensia Diabetes Care, said, “We are thrilled to offer Eversense E3 to people with diabetes in the U.S. and are proud to do this alongside a favorable Payment Assistance and Savings Program. As the longest-lasting CGM system available at up to 6 months of sensor wear, Eversense E3’s offering is truly differentiated and we believe it is important to make the system as affordable as possible. We have been working closely with payers on coverage and our dedicated CGM commercial team is eager to introduce the product to more patients, so they can experience the unique benefits of the Eversense system. As a company with a sole focus on improving the lives of people with diabetes, we can’t wait to get this innovative product into the hands of people with diabetes and their physicians across the country.”

Available in the U.S. now, the Eversense E3 CGM System, which includes an innovative design modification to enhance sensor longevity, offers people with diabetes:

• The longest lasting CGM available, with up to 6-month sensor wear duration and essentially two sensor insertion and removal procedures per year
• Exceptional accuracy, with a mean absolute relative difference (MARD) of 8.5%** demonstrated in the PROMISE Study¹ for the duration of sensor wear
• A fully implantable fluorescence-based sensor, with a removable smart transmitter^† that provides discreet on-body vibe alerts and transmits data to a mobile app
• Fewer calibrations, with primarily one calibration required per day after day 21 of use

“The evolution of continuous glucose monitoring has been one of the biggest developments in diabetes care and the Eversense E3 CGM System is another significant step forward for patients,” added Elaine Anderson, Head of Eversense CGM Business Unit at Ascensia Diabetes Care. “It’s so important to offer choice through a variety of solutions and to listen to what people really need from technology to live life as fully as possible. Eversense E3 exemplifies this approach, offering people with diabetes an exciting new CGM option with outstanding flexibility, convenience and accuracy.”

Patients who are interested in getting started with Eversense can sign up at www.ascensiadiabetes.com/eversense/#get-started. Physicians, nurse practitioners and physician assistants who are interested in offering the Eversense E3 CGM System can sign up at https://www.ascensiadiabetes.com/eversense/become-a-provider/. Alternatively, contact 844- SENSE4U (844-736-7348) to learn more about the first and only long-term implantable CGM system.

ENDS

^*Available immediately to those eligible

^*MARD of 9.1% was observed in primary sensor in the PROMISE Study

^†There is no glucose data generated when the transmitter is removed.

¹Garg S. et al. Evaluation of Accuracy and Safety of the Next-Generation Up to 180-Day Long-Term Implantable Eversense Continuous Glucose Monitoring System: The PROMISE Study. Diabetes Technology & Therapeutics 2021; 24(2): 1-9.DOI: 10.1089/dia.2021.0182

Notes for Editors

About Eversense

The Eversense^® E3 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to 6 months in persons with diabetes age 18 and older. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a trained and certified health care provider. The Eversense CGM System is a prescription device; patients should talk to their health care provider to learn more.

For important safety information, see https://eversensediabetes.com/safety-info/

About Senseonics

Senseonics Holdings, Inc. is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM Systems, Eversense^®, Eversense^® XL and Eversense^® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.

About Ascensia Diabetes Care

Ascensia Diabetes Care is a global company focused entirely on helping people with diabetes. Our mission is to empower those living with diabetes through innovative solutions that simplify and improve their lives.

We are home to the world-renowned CONTOUR^® portfolio of blood glucose monitoring systems and the exclusive global distribution partner for the Eversense^® Continuous Glucose Monitoring Systems from Senseonics. These products combine advanced technology with user-friendly functionality to help people with diabetes manage their condition and make a positive difference to their lives. As a trusted partner in the diabetes community, we collaborate closely with healthcare professionals and other partners to ensure our products meet the highest standards of accuracy, precision and reliability, and that we conduct our business compliantly and with integrity.

Ascensia is a member of PHC Group and was established in 2016 through the acquisition of Bayer Diabetes Care by PHC Holdings Corporation (formerly Panasonic Healthcare). Ascensia products are sold in more than 125 countries. Ascensia has around 1,500 employees and operations in 31 countries.

For further information, please visit the Ascensia Diabetes Care website at: http://www.ascensia.com

^©2022 Ascensia Diabetes Care Holdings AG. All right reserved. Ascensia, the Ascensia Diabetes Care logo and Contour are trademarks and/or registered trademarks of Ascensia Diabetes Care Holdings AG.

For more media enquiries, please contact:

Tim Stamper, Timothy.Stamper@Ascensia.com